Journal of Controlled Release,
Год журнала:
2023,
Номер
362, С. 342 - 355
Опубликована: Сен. 5, 2023
Chronic
retinal
diseases,
such
as
age-related
macular
degeneration
(AMD),
are
a
major
cause
of
global
visual
impairment.
However,
current
treatment
methods
involving
repetitive
intravitreal
injections
pose
financial
and
health
burdens
for
patients.
The
development
controlled
drug
release
systems,
particularly
biological
drugs,
is
still
an
unmet
need
in
prolonging
within
the
vitreous
chamber.
To
address
this,
green
supercritical
carbon
dioxide
(scCO2)
foaming
technology
was
employed
to
manufacture
porous
poly(lactic-co-glycolic
acid)
(PLGA)-based
implants
loaded
with
dexamethasone.
desired
implant
dimensions
were
achieved
through
3D
printing
customised
moulds.
By
varying
depressurisation
rates
during
process,
different
porosities
dexamethasone
successfully
obtained.
These
demonstrated
up
four
months,
surpassing
performance
previously
developed
implants.
In
view
positive
results
obtained,
pilot
study
conducted
using
monoclonal
antibody
bevacizumab
explore
feasibility
this
preparing
intraocular
biologic
molecules.
Overall,
presents
greener
more
sustainable
alternative
conventional
manufacturing
techniques,
suited
drugs
that
susceptible
degradation
under
harsh
conditions.
International Journal of Pharmaceutics,
Год журнала:
2023,
Номер
648, С. 123561 - 123561
Опубликована: Окт. 30, 2023
3D
Printing
(3DP)
of
pharmaceuticals
could
drastically
transform
the
manufacturing
medicines
and
facilitate
widespread
availability
personalised
healthcare.
However,
with
increasing
awareness
environmental
damage
manufacturing,
3DP
must
be
eco-friendly,
especially
when
it
comes
to
carbon
emissions.
This
study
investigated
effects
pharmaceutical
3DP.
Using
Design
Experiments
(DoE)
Machine
Learning
(ML),
we
looked
at
energy
use
in
Fused
Deposition
Modeling
(FDM).
From
136
experimental
runs
across
four
common
dosage
forms,
identified
several
key
parameters
that
contributed
consumption,
consequently
CO
Engineered Regeneration,
Год журнала:
2023,
Номер
4(2), С. 103 - 121
Опубликована: Янв. 15, 2023
Small
incision
lenticule
extraction
(SMILE)
has
become
one
of
the
mainstream
refractive
surgeries
in
recent
years,
with
satisfactory
efficacy,
safety,
and
predictability.
SMILE-derived
lenticule,
byproduct
surgery,
holds
great
potential
clinical
practice
given
its
easy
access
good
biocompatibility.
Numerous
studies
have
been
published
to
describe
applications
correction,
corneal
ectasia
diseases,
defects.
The
feasibility
safety
were
validated
both
animal
models
studies.
Moreover,
preservation
method
is
also
crucial
for
further
promotion
application.
Novel
techniques
are
evaluated
applied
preservation.
We
covered
advances
stromal
lenticules
their
reuse
this
review.
Pharmaceuticals,
Год журнала:
2023,
Номер
16(3), С. 445 - 445
Опубликована: Март 16, 2023
Eyes
are
one
of
the
main
critical
organs
body
that
provide
our
brain
with
most
information
about
surrounding
environment.
Disturbance
in
activity
this
informational
organ,
resulting
from
different
ocular
diseases,
could
affect
quality
life,
so
finding
appropriate
methods
for
treating
disease
has
attracted
lots
attention.
This
is
especially
due
to
ineffectiveness
conventional
therapeutic
method
deliver
drugs
into
interior
parts
eye,
and
also
presence
barriers
such
as
tear
film,
blood-ocular,
blood-retina
barriers.
Recently,
some
novel
techniques,
types
contact
lenses,
micro
nanoneedles
situ
gels,
have
been
introduced
which
can
overcome
previously
mentioned
These
techniques
enhance
bioavailability
components
inside
eyes,
them
posterior
side
release
a
controlled
manner,
reduce
effects
previous
(such
eye
drops).
Accordingly,
review
paper
aims
summarize
evidence
on
effectiveness
these
new
disease,
their
preclinical
clinical
progression,
current
limitations,
future
perspectives.
Materials,
Год журнала:
2023,
Номер
16(10), С. 3653 - 3653
Опубликована: Май 11, 2023
The
field
of
ophthalmology
is
expanding
exponentially,
both
in
terms
diagnostic
and
therapeutic
capabilities,
as
well
the
worldwide
increasing
incidence
eye-related
diseases.
Due
to
an
ageing
population
climate
change,
number
ophthalmic
patients
will
continue
increase,
overwhelming
healthcare
systems
likely
leading
under-treatment
chronic
eye
Since
drops
are
mainstay
therapy,
clinicians
have
long
emphasised
unmet
need
for
ocular
drug
delivery.
Alternative
methods,
i.e.,
with
better
compliance,
stability
longevity
delivery,
would
be
preferred.
Several
approaches
materials
being
studied
used
overcome
these
drawbacks.
We
believe
that
drug-loaded
contact
lenses
among
most
promising
a
real
step
toward
dropless
potentially
transformation
clinical
practice.
In
this
review,
we
outline
current
role
focusing
on
materials,
binding
preparation,
concluding
look
at
future
developments.
Journal of Controlled Release,
Год журнала:
2023,
Номер
362, С. 342 - 355
Опубликована: Сен. 5, 2023
Chronic
retinal
diseases,
such
as
age-related
macular
degeneration
(AMD),
are
a
major
cause
of
global
visual
impairment.
However,
current
treatment
methods
involving
repetitive
intravitreal
injections
pose
financial
and
health
burdens
for
patients.
The
development
controlled
drug
release
systems,
particularly
biological
drugs,
is
still
an
unmet
need
in
prolonging
within
the
vitreous
chamber.
To
address
this,
green
supercritical
carbon
dioxide
(scCO2)
foaming
technology
was
employed
to
manufacture
porous
poly(lactic-co-glycolic
acid)
(PLGA)-based
implants
loaded
with
dexamethasone.
desired
implant
dimensions
were
achieved
through
3D
printing
customised
moulds.
By
varying
depressurisation
rates
during
process,
different
porosities
dexamethasone
successfully
obtained.
These
demonstrated
up
four
months,
surpassing
performance
previously
developed
implants.
In
view
positive
results
obtained,
pilot
study
conducted
using
monoclonal
antibody
bevacizumab
explore
feasibility
this
preparing
intraocular
biologic
molecules.
Overall,
presents
greener
more
sustainable
alternative
conventional
manufacturing
techniques,
suited
drugs
that
susceptible
degradation
under
harsh
conditions.
